BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 34334496)

  • 1. cAMP Signaling Pathway Prevents Dasatinib-Induced Vascular Hyperpermeability.
    Aoyama T; Kuriyama H; Sato Y; Imai S; Kashiwagi H; Sugawara M; Takekuma Y
    Biol Pharm Bull; 2021; 44(8):1101-1110. PubMed ID: 34334496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bosutinib, dasatinib, imatinib, nilotinib, and ponatinib differentially affect the vascular molecular pathways and functionality of human endothelial cells.
    Gover-Proaktor A; Granot G; Pasmanik-Chor M; Pasvolsky O; Shapira S; Raz O; Raanani P; Leader A
    Leuk Lymphoma; 2019 Jan; 60(1):189-199. PubMed ID: 29741440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dasatinib induces endothelial-to-mesenchymal transition in human vascular-endothelial cells: counteracted by cotreatment with bosutinib.
    Alkebsi L; Wang X; Ohkawara H; Fukatsu M; Mori H; Ikezoe T
    Int J Hematol; 2021 Mar; 113(3):441-455. PubMed ID: 33392972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dasatinib increases endothelial permeability leading to pleural effusion.
    Phan C; Jutant EM; Tu L; Thuillet R; Seferian A; Montani D; Huertas A; Bezu JV; Breijer F; Vonk Noordegraaf A; Humbert M; Aman J; Guignabert C
    Eur Respir J; 2018 Jan; 51(1):. PubMed ID: 29348177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bosutinib - related pleural effusion in patients with chronic myeloid leukemia.
    Yüzbaşıoğlu MB; Eşkazan AE
    Expert Opin Drug Saf; 2021 Apr; 20(4):379-381. PubMed ID: 33339467
    [No Abstract]   [Full Text] [Related]  

  • 6. Pleural Effusion in Dasatinib-Treated Patients With Chronic Myeloid Leukemia in Chronic Phase: Identification and Management.
    Cortes JE; Jimenez CA; Mauro MJ; Geyer A; Pinilla-Ibarz J; Smith BD
    Clin Lymphoma Myeloma Leuk; 2017 Feb; 17(2):78-82. PubMed ID: 28082112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beneficial effects of the Src inhibitor, dasatinib, on breakdown of the blood-retinal barrier.
    Kim SR; Suh W
    Arch Pharm Res; 2017 Feb; 40(2):197-203. PubMed ID: 27988882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bosutinib-induced massive pleural effusion: Cross-intolerance with all tyrosine kinase inhibitors.
    Aslan NA; Hıncal HO; Elver Ö; Erol V; Güler N
    J Oncol Pharm Pract; 2023 Mar; 29(2):511-516. PubMed ID: 35821583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lupus-like symptoms with anti-RNP/Sm and anti-nuclear antibodies positivity: An extremely rare adverse event of dasatinib.
    Maral S; Bakanay SM; Kucuksahin O; Dilek I
    J Oncol Pharm Pract; 2020 Apr; 26(3):738-741. PubMed ID: 31359838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bosutinib: a review of its use in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
    Syed YY; McCormack PL; Plosker GL
    BioDrugs; 2014 Feb; 28(1):107-20. PubMed ID: 24420842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human mesenchymal stem cells inhibit vascular permeability by modulating vascular endothelial cadherin/β-catenin signaling.
    Pati S; Khakoo AY; Zhao J; Jimenez F; Gerber MH; Harting M; Redell JB; Grill R; Matsuo Y; Guha S; Cox CS; Reitz MS; Holcomb JB; Dash PK
    Stem Cells Dev; 2011 Jan; 20(1):89-101. PubMed ID: 20446815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity.
    Schiffer CA; Cortes JE; Hochhaus A; Saglio G; le Coutre P; Porkka K; Mustjoki S; Mohamed H; Shah NP
    Cancer; 2016 May; 122(9):1398-407. PubMed ID: 26998677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deterioration of pulmonary hypertension and pleural effusion with bosutinib following dasatinib lung toxicity.
    Riou M; Seferian A; Savale L; Chaumais MC; Guignabert C; Canuet M; Magro P; Rea D; Sitbon O; Jaïs X; Humbert M; Montani D
    Eur Respir J; 2016 Nov; 48(5):1517-1519. PubMed ID: 27799395
    [No Abstract]   [Full Text] [Related]  

  • 14. An Analysis of Dasatinib Treatment Patterns in Patients with Chronic Myeloid Leukemia after Experiencing Pleural Effusion during Dasatinib Therapy.
    McBride A; Brokars J; Reddy SR; Chang E; Tarbox MH; LeBlanc TW
    Acta Haematol; 2023; 146(4):259-266. PubMed ID: 37037194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dipeptidyl Peptidase-4 Inhibitor Increases Vascular Leakage in Retina through VE-cadherin Phosphorylation.
    Lee CS; Kim YG; Cho HJ; Park J; Jeong H; Lee SE; Lee SP; Kang HJ; Kim HS
    Sci Rep; 2016 Jul; 6():29393. PubMed ID: 27381080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy of tolvaptan in treating dasatinib-induced pleural effusions in patients with chronic myelogenous leukemia.
    Aoyama R; Ishikawa J; Harada K
    J Cardiol; 2020 Feb; 75(2):203-207. PubMed ID: 31416783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of pleural effusion with an early molecular response in patients with newly diagnosed chronic-phase chronic myeloid leukemia receiving dasatinib: Results of a D-First study.
    Hagihara M; Iriyama N; Yoshida C; Wakita H; Chiba S; Okamoto S; Kawakami K; Takezako N; Kumagai T; Inokuchi K; Ohyashiki K; Taguchi J; Yano S; Igarashi T; Kouzai Y; Morita S; Sakamoto J; Sakamaki H
    Oncol Rep; 2016 Nov; 36(5):2976-2982. PubMed ID: 27665844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of bosutinib in chronic phase CML patients developing pleural effusion under dasatinib therapy.
    Tiribelli M; Abruzzese E; Capodanno I; Sorà F; Trabacchi E; Iurlo A; Luciano L; Binotto G; Bonifacio M; Annunziata M; Crugnola M; Fanin R
    Ann Hematol; 2019 Nov; 98(11):2609-2611. PubMed ID: 31529281
    [No Abstract]   [Full Text] [Related]  

  • 19. Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034.
    Shah NP; Rousselot P; Schiffer C; Rea D; Cortes JE; Milone J; Mohamed H; Healey D; Kantarjian H; Hochhaus A; Saglio G
    Am J Hematol; 2016 Sep; 91(9):869-74. PubMed ID: 27192969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors.
    Weatherald J; Bondeelle L; Chaumais MC; Guignabert C; Savale L; Jaïs X; Sitbon O; Rousselot P; Humbert M; Bergeron A; Montani D
    Eur Respir J; 2020 Oct; 56(4):. PubMed ID: 32527740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.